Fate of primary cells at the G1/S boundary after polo-like kinase 1 inhibition by SBE13

Cell Cycle

Volumn 10, Issue 4, 2011, Pages 708-720

  Keppner, Sarah ^a   Proschak, Ewgenij ^a   Schneider, Gisbert ^b   Spänkuch, Birgit ^a  

^a GOETHE UNIVERSITY   (Germany)

^b ETH ZURICH   (Switzerland)

Author keywords

Cell cycle; Polo like kinase 1; Primary cells; SBE13; Type II kinase inhibitor

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CASPASE 3; CASPASE 7; CELL CYCLE PROTEIN; POLO LIKE KINASE 1; PROTEIN KINASE INHIBITOR; SBE 13; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER RESEARCH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ASSAY; ENZYME INHIBITION; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; NONHUMAN; WESTERN BLOTTING;

EID: 79951940586     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.4.14898     Document Type: Article

References (40)

1. Glover DM, Hagan IM, Tavares AA. Polo-like kinases: A team that plays throughout mitosis. Genes Dev 1998; 12:3777-87. (Pubitemid 29024839)
2. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H, et al. Induction and downregulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994; 91:1736-40. (Pubitemid 24080280)
3. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
4. Schmit TL, Zhong W, Nihal M, Ahmad N. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009; 8:2697-702.
5. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24:267-76. (Pubitemid 40188607)
6. Rodel F, Keppner S, Capalbo G, Bashary R, Kaufmann M, Rodel C, et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010; 177:918-29.
7. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001; 410:215-20. (Pubitemid 32216594)
8. Yuan J, Eckerdt F, Bereiter-Hahn J, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 2002; 21:8282-92. (Pubitemid 35477868)
9. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002; 3:341-8. (Pubitemid 34467604)
10. Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000; 11:615-23. (Pubitemid 32042984)
11. van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5:853-64. (Pubitemid 44145580)
12. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94. (Pubitemid 36576886)
13. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115:978-85. (Pubitemid 40489402)
14. Ahmad N. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J 2004; 18:5-7.
15. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135:1701-13. (Pubitemid 27036434)
16. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells. J Natl Cancer Inst 2002; 94:1863-77. (Pubitemid 36104631)
17. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002; 21:3162-71. (Pubitemid 34548087)
18. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96:862-72. (Pubitemid 38807607)
19. Liu X, Erikson RL. Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle 2003; 2:424-5.
20. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26:5793-807. (Pubitemid 47312808)
21. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. Ataxia-telangiectasia mutated (ATM)- dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J Biol Chem 2007; 282:17501-6. (Pubitemid 47100270)
22. Li H, Wang Y, Liu X. Plk1-dependent Phosphorylation Regulates Functions of DNA Topoisomerase II{alpha} in Cell Cycle Progression. J Biol Chem 2008; 283:6209-21.
23. Lenart P, Petronczki M, Steegmaier M, Di FB, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of pololike kinase 1. Curr Biol 2007; 17:304-15.
24. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-22. (Pubitemid 46241881)
25. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2:358-64. (Pubitemid 43936934)
26. Keppner S, Proschak E, Schneider G, Spankuch B. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem 2009; 4:1806-9.
27. Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spankuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle 2010; 9:761-74.
28. Matthew EM, Yen TJ, Dicker DT, Dorsey JF, Yang W, Navaraj A, et al. Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle 2007; 6:2571-8. (Pubitemid 350058677)
29. Lei M, Erikson RL. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 2008; 27:3935-43. (Pubitemid 351913640)
30. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643-60.
31. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99. (Pubitemid 39070849)
32. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15:3094-102.
33. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26:5511-7.
34. Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, et al. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Bioorg Med Chem Lett 2009; 19:4673-8.
35. Yim H, Erikson RL. Polo-like kinase-1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol 2009; 29:2609-21.
36. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003; 3:111-5. (Pubitemid 37443384)
37. Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R, Oren M. The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death Differ 2005; 12:1578-87. (Pubitemid 41679163)
38. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002; 16:984-93. (Pubitemid 34408547)
39. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB. Topical treatment with inhibitors of the phosphatidylinositol- 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004; 64:2552-60. (Pubitemid 38523912)
40. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K. Downregulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo. Cancer Res 2006; 66:5836-46. (Pubitemid 43927138)